Saturday 17 October 2026
Export NKGN’s income statement to Excel — free account
NKGen Biotech, Inc.
NKGN Healthcare Biotechnology
NKGen Biotech, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $77,000.00. In the quarter to March 2025, EPS grew 232.0% and free cash flow grew 28.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.01
0.00
0.00%
Follow NKGN
NKGen Biotech, Inc. (NKGN) P/E ratio
NKGen Biotech, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 241× (May 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
Against its own ten years
Low 0.0×
High 241×
Ten-year median
0.0×
Current reading's percentile
90
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BOLT Bolt Biotherapeutics, Inc. compare | n/m |
| MTVA MetaVia Inc. compare | n/m |
| IMRN IMMURON compare | n/m |
| SNTI Senti Biosciences, Inc. compare | n/m |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR compare | n/m |
| ADIL Adial Pharmaceuticals, Inc. compare | n/m |
| NKGN NKGen Biotech, Inc. | n/m |
| JAGX Jaguar Animal Health, Inc. compare | 0.0× |
| CSCIF COSCIENS Biopharma Inc. compare | 1.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)